We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effect of immunogenetics polymorphism and expression on direct-acting antiviral drug response in chronic hepatitis C.
- Authors
Abdelaziz, Aya Ismail; Abdelsameea, Eman; Abdel-Samiee, Mohamed; Ghanem, Samar E.; Wahdan, Sara A.; Elsherbiny, Doaa A.; Zakaria, Zeinab; Azab, Samar S.
- Abstract
The prevalence of HCV infection in Egypt has decreased following the introduction of direct-acting antiviral therapy. However, treatment response is influenced by various factors, particularly host immunogenetics such as IL-28B and FOXP3 polymorphisms. The current study examined the impact of SNPs in the FOXP3 gene promoter region on HCV-infected Egyptian patients, along with SNPs in the IL28B gene.This study involved 99 HCV patients who achieved SVR12 after a 12 week DAA treatment while 63 HCV patients experienced treatment failure. IL28B rs12979860 SNP was identified using real-time PCR, while IL28B rs8099917, FOXP3 rs3761548, and rs2232365 SNPs were analyzed using RFLP-PCR. Serum levels of IL28B and FOXP3 were quantified using ELISA technique in representative samples from both groups. The IL28B rs12979860 T > C (P = 0.013) and FOXP3 rs2232365 A > G polymorphisms (P = 0.008) were found to significantly increase the risk of non-response. Responders had higher IL28B serum levels (P = 0.046) and lower FOXP3 levels (P < 0.001) compared to non-responders. Regression analysis showed an association between IL28B rs12979860 and FOXP3 rs2232365 with treatment response, independent of age and gender. A predictive model was developed with 76.2% sensitivity and 91.9% specificity for estimating DAAs response in HCV patients.Our findings confirmed the IL28B rs12979860 T > C and FOXP3 rs2232365 A > G polymorphisms significantly affect DAA treatment response in HCV Egyptian patients. Lower levels of IL-28B along with higher levels of FOXP3 are linked to poor response. Our results may lead to new insights into DAA responsiveness contributing to personalized medicine and improving therapeutic decision-making for HCV patients.
- Subjects
EGYPTIANS; IMMUNOGENETICS; GENETIC polymorphisms; PROMOTERS (Genetics); SINGLE nucleotide polymorphisms
- Publication
Clinical & Experimental Medicine, 2024, Vol 24, Issue 1, p1
- ISSN
1591-8890
- Publication type
Article
- DOI
10.1007/s10238-024-01432-x